Yuyu Pharma Promotes New Drug Candidate for Dry Eye Syndrome at American Academy of Ophthalmology

CEO Won-Sang Yoo of Yuyu Pharma explaining YP-P10 to American KOL ophthalmologists.

[Asia Economy Reporter Lee Gwan-joo] Yuyu Pharma announced on the 4th that it promoted the new peptide drug for dry eye treatment, 'YP-P10,' at the annual meeting of the American Academy of Ophthalmology (AAO) held in Chicago, USA.

Yuyu Pharma stated that CEO Yoo Won-sang explained YP-P10 to KOL (Key Opinion Leader) ophthalmologists and conducted interviews with numerous global ophthalmology specialized media outlets.

The AAO is one of the largest ophthalmology societies in the world, with over 32,000 ophthalmologists as members, where ophthalmologists and faculty gather annually to share new technologies and information.

YP-P10 is a bio new drug utilizing synthetic peptides, which demonstrated superior anti-inflammatory effects compared to existing drugs in preclinical trials. It aims for fundamental treatment of dry eye syndrome through anti-inflammatory effects and corneal damage improvement. Currently, Phase 2 clinical trials are underway at seven hospitals in the United States, involving 240 dry eye patients.

CEO Yoo said, "At this AAO, we informed the U.S. ophthalmic medical staff about the current status of YP-P10 research and achieved the desired promotional effect through positive feedback, including expectations for future research results. We plan to attend various global medical societies and conferences and establish an English website introducing YP-P10 research to continuously promote YP-P10 to ophthalmologists worldwide, including in the U.S. and Europe."

This content was produced with the assistance of AI translation services.